|SLXCF.OB...these guys are making very good progress--I like the play. $.65. 23m out.|
Stellar Pharmaceuticals Provides Guidance for 2009 Second Quarter Revenues in Excess of One Million Dollars (CDN)
LONDON, ONTARIO--(Marketwire - 06/19/09) - Stellar Pharmaceuticals Inc. ("Stellar" or the "Company") (OTC.BB:SLXCF - News) a Canadian pharmaceutical developer and marketer of high quality, cost effective products for select health care markets, today announced that its second quarter revenues will exceed one million dollars, an increase of approximately 55% over revenues reported for the same quarter in 2008 and the Company also expects that it will be profitable for the period.
Peter Riehl, Stellar's President and CEO, stated, "This is the strongest second quarter in the Company's history, with revenues up substantially in all markets. The Company expects to also be profitable for the period, making this the third consecutive quarter that the Company has shown a profit. We are very pleased to see this growth given the challenging economic times."
About Stellar Pharmaceuticals Inc.
Stellar has developed and is marketing direct in Canada and in countries around the world through out-license agreements two products based on its core polysaccharide technology: NeoVisc?, for the treatment of osteoarthritis; and Uracyst?, its patented technology for treatment of interstitial cystitis/painful bladder syndrome an inflammatory disease of the urinary bladder wall. Stellar also has in-licensing agreement for the distribution and sale of NMP22? BladderChek?, a proteomics-based diagnostic test for the diagnosis and monitoring of bladder cancer.
Stellar Pharmaceuticals Announces the Launch of Neovisc(R) Single Dose
* Press Release
* Source: Stellar Pharmaceuticals Inc.
* On Thursday June 18, 2009, 9:08 am EDT
LONDON, ONTARIO--(Marketwire - 06/18/09) - Stellar Pharmaceuticals Inc. ("Stellar" or "the Company") (OTC.BB:SLXCF - News), a Canadian pharmaceutical developer and marketer of high quality, cost-effective products for select health care markets, announced at their annual shareholders meeting held on June 17, the launch of NeoVisc? Single Dose in the Canadian market.
Peter Riehl, Stellar's President & CEO, stated, "The osteoarthritis market is an extremely large market, currently affecting about 10% of the global population. As our population continues to age, the prevalence of osteoarthritis will also grow providing tremendous opportunity for products such as NeoVisc. The Company is pleased to be able to offer the convenience of NeoVisc Single Dose, as a single injection alternative, to physicians and their patients. Although the relief period on the single dose may not be as long as the current 3 dose NeoVisc treatment, the Company felt is was important to respond to market demand for convenience and yet maintain an affordable alternative."
Stellar is currently the only company across Canada to provide a natural linear molecular hyaluronate product in both a single and three injectable dose format.
NeoVisc is a viscosupplement that when injected into the effected joints, offers patients a drug-free method to treat the pain of osteoarthritis ("OA"). NeoVisc is available in Canada, Europe, Asia, Middle East and the Caribbean as a three injection product administered over a two-week period. The 3 dose NeoVisc has been shown to provide symptomatic relief of OA pain for an average of 6-12 months. There are certain situations however, where administering the 3 dose treatment is difficult to schedule for certain patients in a busy practice. NeoVisc Single Dose provides physicians and patients the convenience of a single injection treatment. This single injection provides symptomatic relief but usually over a shorter duration than the 3 dose NeoVisc. Both the NeoVisc Single Dose and 3 dose NeoVisc use a natural, linear hyaluronan derived from a fermentation process, unlike competitors that use an altered, cross-linked hyaluronan.